SCHEMBL13282969

SCHEMBL13282969

CCCc1cc(-c2n[nH]c3cc(O)ccc23)ccc1Oc1cccc(C[C@@]2(C)OC(=O)NC2=O)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 3/20 0.41
JAK1 P23458 4/20 0.38
JAK3 P52333 4/20 0.38
JAK2 O60674 3/20 0.38
TYK2 P29597 3/20 0.38
FGFR2 P21802 2/20 0.37
FGFR3 P22607 2/20 0.37
PDPK1 O15530 1/20 0.36
HSP90AB1 P08238 1/20 0.36
CDK4 P11802 2/20 0.35
CCNA2 P20248 2/20 0.35
CCND1 P24385 2/20 0.35
CDK2 P24941 2/20 0.35
CCND3 P30281 2/20 0.35
CHEK1 O14757 1/20 0.35
KDR P35968 1/20 0.35
NR1H2 P55055 2/20 0.34
NR1H3 Q13133 2/20 0.34
PPARG P37231 6/20 0.34
PPARD Q03181 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13134027 0.92 FGFR2 (0.37) FGFR1FGFR2FGFR3NR1H2NR1H3
SCHEMBL3551384 0.91 MAP2K4 (0.36) FGFR1FGFR2FGFR3NR1H2NR1H3
SCHEMBL3551052 0.91 FGFR2 (0.36) FGFR1JAK1JAK3FGFR2FGFR3
SCHEMBL13282972 0.87 JAK2 (0.40) FGFR1JAK1JAK3JAK2TYK2
SCHEMBL3659688 0.86 PPARG (0.40) NR1H2NR1H3PPARGPPARDPPARA
SCHEMBL3659685 0.86 PPARG (0.40) NR1H2NR1H3PPARGPPARDPPARA
SCHEMBL13114528 0.79 PPARG (0.42) NR1H2NR1H3PPARGPPARDPPARA
SCHEMBL3548104 0.79 PPARG (0.42) NR1H2NR1H3PPARGPPARDPPARA
SCHEMBL3544800 0.79 PPARG (0.34) NR1H2NR1H3PPARGPPARDPPARA
SCHEMBL13114536 0.79 NAMPT (0.36) NR1H2NR1H3PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100168164-A1 Antidiabetic Oxazolidinediones and Thiazolidinediones MERCK SHARP & DOHME CORP. 2010-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168164-A1 Antidiabetic Oxazolidinediones and Thiazolidinediones PPARD, PPARA, PPARG FGFR1 528/4885JAK1 1192/4885JAK3 671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.